Category - Developments

Developments

Advaxis reports positive initial Phase 1 data for cancer vaccine

Advaxis’ (NASDAQ:ADXS) ADSX-NEO has demonstrated significant anti-tumor activity in a Phase 1 study of patients with certain types of advanced or metastatic solid tumors. ADXS-NEO is a live, attenuated Listeria...

April 2, 2019

Developments

Ocutrx Vision receives second patent for augmented reality glasses eye tracking technology

Closely-held Ocutrx Vision Technologies announced issuance of the company’s second U.S. patent, which will protect the company’s unique eye tracking technology for patients with macular degeneration and other low vision...

April 2, 2019

Developments

Imagin Medical successfully completes i/Blue functional unit assembly

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart: DPD2) has completed assembly of its i/Blue Imaging System’s functional unit, which has met the company’s pre-established performance expectations. The...

April 2, 2019

Developments

Aphria launches CBD-based products in Germany

Aphria (TSX:APHA; NYSE:APHA) has launched CannRelief, a cannabidiol (CBD)-based nutraceutical and cosmetics line, through its subsidiary Aphria Deutschland. Featuring hemp-derived CBD, CannRelief products are produced...

April 1, 2019

Developments

Blume raises seed capital for young women’s self help and period products

Closely-held Blume, a young women’s self help and periods products company, raised $3.3-million in a seed funding round, led by Grace Chou and Victoria Treyger, partners at Felicis Ventures, with participation from...

April 1, 2019

Developments

CHMP affirms omega-3s do not prevent further problems after heart attack

The European Medicine Agency’s (EMA) advisory committee (CHMP) affirmed that a 1gm daily dose of omega-3s are not effective in preventing further cardiovascular (CV) problems in patients who have had a heart attack. The...

March 29, 2019

Developments

Supernus Pharma again posts positive Phase 3 ADHD data

Supernus Pharma (NASDAQ:SUPN) announced top-line results from P304, its Phase 3 study of SPN-812 in adolescents with attention deficit hyperactivity disorder (ADHD). SPN-812 is a non-stimulant serotonin norepinephrine...

March 29, 2019

Developments

Fluidigm introduces new immune profiling system

Fluidigm’s (NASDAQ:FLDM) new immune profiling system, Maxpar Direct, quantifies immune cell populations with automated five-minute results reporting. Maxpar Direct uses a single-tube workflow to profile 37 different...

March 28, 2019

Developments

Neuronetics receives Japanese reimbursement for NeuroStar’s TMS Therapy

Transcranial magnetic stimulation (TMS) pioneer, Neuronetics (NASDQ:STIM), received reimbursement approval from Japan’s Central Social Insurance Medical Council for its NeuroStar Advanced Therapy for the treatment...

March 28, 2019

Developments

Titan Pharma in pact with AppianRx for comprehensive Probuphine patient support services

Titan Pharmaceuticals (NASDAQ:TTNP) executed a service agreement with AppianRx, a specialty healthcare solutions company, to provide a full suite of patient support services related to Titan’s Probuphine implant, a...

March 28, 2019

Category - Developments

Subscribe